Tonix Pharmaceuticals Enrolls First Participant in the PRECISION Study, an Observational Study to Facilitate Development of Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics October 15, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Plan to Complete the Phase 3 RELIEF Study of TNX-102 SL for Management of Fibromyalgia with Currently Enrolled Participants Based on Results of Interim Analysis September 29, 2020 • 4:05 PM EDT
Tonix Pharmaceuticals Completes Purchase of Facility to House Advanced Development Center (ADC) for Vaccine Programs September 28, 2020 • 4:15 PM EDT
Tonix Pharmaceuticals to Host Live Webinar: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19? September 17, 2020 • 9:17 AM EDT
Tonix Pharmaceuticals Enrolls First Patient in COV-LOGIC, an Observational Study to Assess Antibody and T Cell Responses to SARS-CoV-2, the Virus that Causes COVID-19 September 15, 2020 • 9:00 AM EDT
Tonix Pharmaceuticals Initiates Enrollment in Second Potentially Pivotal Phase 3 Study, the RALLY Study, of TNX-102 SL for the Management of Fibromyalgia September 3, 2020 • 9:00 AM EDT
Tonix Pharmaceuticals to Participate in Upcoming September Virtual Investor Conferences August 27, 2020 • 7:30 AM EDT
Tonix Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights August 10, 2020 • 8:45 AM EDT
Tonix Pharmaceuticals Announces Clearance of IND for TNX-102 SL for Treatment of Alcohol Use Disorder August 6, 2020 • 9:00 AM EDT
